SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience

Sandra Mossuto, Enrico Attardi, Francesco Alesi, Emanuele Angelucci, Enrico Ballestreri, Massimo Bernardi, Gianni Binotto, Costanza Bosi, Anna Calvisi, Isabella Capodanno, Antonella Carbone, Andrea Castelli, Marco Cerrano, Rosanna Ciancia, Daniela Cilloni, Carmine Selleri, Agostino Tafuri, Valeria Santini, Massimo Bernardi, Gianni Binotto, Costanza Bosi, Anna Calvisi, Isabella Capodanno, Estefania Oliva, Giuseppe A. Palumbo, Anna Calvisi, Isabella Capodanno, Estefania Oliva, Giuseppe A. Palumbo, Massimo Bernardi.

Correspondence: Valeria Santini (e-mail: valeria.santini@unifi.it).
Myelodysplastic syndrome patients are subjects of advanced age, vulnerable and frail, whose outcome is heavily influenced by pre-existing comorbidities worsening the hematologic condition. Infections are a rather common cause of death (around 30%), especially, but not only, for IPSS-R higher risk patients. In MDS there is a significant impairment of lymphopoiesis, resulting in lymphopenia (ALC < 1.0 × 10^9/l) in around 38% of MDS patients and poor prognosis. Data on innate and adaptive immune systems (either disease related or due to immunosenescence) and the subsequent supposed susceptibility and incidence of viral infections in MDS are scarce.

With all these considerations in mind, at Coronavirus outbreak in Italy, the spread of the COVID-19 pandemic was so extremely rapid that we were expecting to face in short times a very large number of severely symptomatic MDS patients and tried to rapidly learn from the earlier and more severely hit areas. As per April 28, date until which we collected our data, and in full emergency, the number of diagnosed cases of SARS-CoV2 in Italy was 199,470. In the same period, in the general population of the area (62.4% of total Italian cases), the incidence of SARS-CoV-2 infection sent for confirmation in the national reference central laboratory (Istituto superiore di sanità -ISS). Confirmed SARS-CoV-2 was diagnosed in 63/305 tested cases (20.6%), globally in 63/5326 (1.18%) MDS patients, in the time frame indicated above. Median age of affected MDS patients was 78 years.

We evaluated the distribution of SARS-CoV-2 cases dividing the Country into three macro-regions, considering adhering Centers and the epidemiology and cumulative incidence of COVID-19 in Italy. In the 3 Regions of Northern Italy (Lombardia, Piemonte and Emilia Romagna), SARS-CoV-2 > 500/100,000 inhabitants, as per April 28, 2020, Rome and surroundings (specific GROM Registry), and Rest of Italy (Table 1). The majority of SARS-CoV-2 cases and cumulative incidence among MDS patients was localized in the 3 Regions of Northern Italy (LPE) (1.6%), consistent with the data of COVID-19 epidemic in the general population of the area (62.4% of total Italian cases), while in Rome and Rest of Italy it was < 1%, (0.3 and 0.85% respectively). Median age of affected MDS patients in LPE Regions was 81 years, in Rome 71 years and in the rest of Italy 77 years.

At the time of analysis, only 33/63 patients were alive, indicating a lethality rate significantly higher than that of non-MDS population (same age range 70–79 years: 28.9% deceased, lethality 24%).

Available details on demographics, clinical characteristics and treatment of 63 MDS patients with SARS-CoV-2 are indicated in Table 2. It is evident that SARS-CoV-2 affected prevalently male subjects, confirming the observation in non-MDS Italian affected population aged 70 to 79 yrs. In particular, although numbers are extremely small, the lethality rate was higher in male MDS patients (73% of total deaths). To note, the same trend was noted for male patient in the general population infected (lethality for male 29.5% vs 16.7% for female aged 70–79 years), while survival of MDS patients was not apparently influenced by age (median age 78 years in both groups). Reported cause of death for all 30 cases was respiratory failure, in 82% of cases COVID-19 was complicated by bacterial pneumonia and 5% cardiac failure. ARDS was indicated in 50% of deceased cases. Regarding IPSS-R risk categories, the majority of patients who recovered were lower risk ones (62%), while deceased patients were in the great majority IPSS-R higher risk ones (17/30). There is no statistically significant difference for infection, gravity of infection or survival according to the type of treatment received, in part due to the small figures when we come to the granularity of therapies. A higher proportion of patients was in treatment with azacitidine, consistent with their diagnosis of IPSS-R higher risk MDS. The totality of the MDS patients who were diagnosed with SARS-CoV-2 had multiple severe comorbidities (> 3 comorbidities 80% of cases).

A few patients received only supportive care for COVID-19 infection, either for milder clinical presentation (3/33) or, on the contrary, for a rapid and extremely aggressive onset leading to early death (3/30). In the majority of cases, MDS specific therapies were suspended.

The impact of SARS-CoV-2 on the frail MDS population was evaluated in a limited time frame during the peak of the pandemic in Italy and the strict national lockdown. Incidence of symptomatic infection was not as relevant as expected in MDS patients for whom neutropenia, lymphopenia, stress erythropoiesis and iron overload could have determined a substantial susceptibility to and gravity of SARS-CoV-2. Similar observations were recently reported, in a much younger population of beta thalassemic patients. Median age of SARS-CoV-2 MDS patients was higher than that of the affected Italian MDS population, and this, together with comorbidities, may account for the high lethality rate observed. This report is limited and

| Region                  | N’ of MDS Patients Registered | SARS-CoV-2 Positive MDS Patients (%) |
|-------------------------|------------------------------|-------------------------------------|
| LPE Regions*            | 2689 (51%)                  | 44/63 (70%)                         |
| Rome and surroundings   | 767 (14%)                   | 3/63 (5%)                           |
| Rest of Italy           | 1870 (35%)                  | 16/63 (25%)                         |
| Total                   | 5326 (100%)                 | 63 (100%)                           |

According to the Centers that provided data, Italian territory was subdivided into 3 macroregions. Following the differences in cumulative incidence of COVID-19 infection in general population. Regions with a cumulative incidence of SARS-CoV-2 > 500/100,000 inhabitants, as per April 28th, that is Lombardia, Piemonte, and Emilia Romagna (*LPE) were analyzed separately. Globally, 1.18% of MDS patients under treatment or observation in the period indicated was affected by SARS-CoV-2. 20.6% of patients who underwent molecular testing, with a median age of 78 years.
preliminary (early landmark date), produced during the health emergency. Here we share the international problem of general epidemiology of SARS-CoV-2. In fact, we do not have data for asymptomatic infected MDS patients, for whom diagnostic procedures were not performed, and still complete data are lacking. At present, after resolution of the health emergency, routine serology evaluation of COVID-19 antibodies is ongoing for MDS patients managed in our Centers.

References
1. Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116: 2174–2179.
2. Nachtkamp K, Stark R, Strupp C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95:937–944.
3. Latagliata R, Niscola P, Fianchi L, et al. Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. Hematol Oncol. 2020;38:189–196.
4. Silzie T, Blum S, Schuler E, et al. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. Blood Cancer J. 2019;9:63.
5. Girmenia C, Candoni A, Delia M, et al. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood Rev. 2019;34:16–25.
6. Fagiuoli S, Lorini FL, Remuzzi G. Adaptations and lessons in the province of Bergamo. N Engl J Med. 2020;382:e71.
7. Istituto Superiore Sanità. https://www.epicentro.iss.it/. Bolletino sorveglianza integrata Covid 19-19-28 aprile 2020. Accessed September 10, 2020.
8. Ministero della Salute. https://www.salute.gov.it. Accessed September 10, 2020.
9. Motta I, Migone De Amicis M, Pinto VM, et al. SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. Am J Hematol. 2020;95:E198–E199.
10. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 August 13. [Epub ahead of print].

Table 2
Demographics and Clinical Characteristics of MDS Patients Diagnosed with SARS-CoV-2 and Available Data on MDS and COVID-19 Treatment.

|                           | N° of MDS patients alive | N° of MDS patients deceased |
|---------------------------|--------------------------|-----------------------------|
| Age (median) Years        | 78                       | 78                          |
| Sex MF                   | 42/21                    | 20/13                       | 22/8 |
| IPSS-R Very low          | 0/33                     | 19/33                       | 4/30 |
| Low                      | 19/33                    | 18/33                       | 7/30 |
| Intermediate             | 8/33                     | 2/33                        | 11/30 |
| High                     | 2/33                     | 2/33                        | 6/30 |
| Very High                | 2/33                     | 2/33                        | 0/30 |
| MDS Therapy              |                          |                             |
| ESA                       | 16/33                    | 4/30                        |
| HMA                      | 4/33                     | 15/30                       |
| HMA+ venetoclax           | 1/33                     | 5/30                        |
| BSC                      | 3/33                     | 2/33                        | 1/30 |
| BSC+ chelation            | 1/33                     | 1/30                        | 2/30 |
| Lenalidomide             | -                        | -                           |
| Danazol                  | -                        | -                           |
| WW                       | 3/33                     | 3/30                        |
| COVID 19 Therapy          |                          |                             |
| Antibiotics              | 26/33                    | 30/30                       |
| Hydroxychloroquine       | 24/33                    | 24/33                       |
| Steroids                 | 4/33                     | 4/30                        |
| LMW Heparin              | 6/33                     | 10/30                       |
| Lopinavir/Ritonavir       | 1/33                     | 1/30                        |
| Darunavir/Cobicistat      | 3/33                     | 10/30                       |
| ICU                      | 12/33                    | 17/30                       |
| Supportive therapy only   | 3/33                     | 3/30                        |
| Antivirals (not specified)| 1/33                     | 1/30                        |
| Tocilizumab              | 2/33                     | 0/30                        |